Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Spain / NCT05729581
Active, not recruiting Not applicable

Effectiveness of Educational Intervention on Sustainable Breastfeeding: The GREEN MOTHER Project

NCT05729581 · tracked via the Priya Life Science Spain tracker
Sponsor
Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Phase
Not applicable
Started
2022-04-11
Last updated
2026-08-06

Condition(s) studied

Healthy DietHealth BehaviourEnvironmental-Pollution-Related ConditionMothersChild, Only

Investigational drug(s) / intervention(s)

The educational programme on sustainable and healthy diet and breastfeeding

The educational programme on sustainable and healthy diet and breastfeeding: In the interventional group the educational programme of sustainable diet and breastfeeding will be provided before the delivery to see the impact on the prevalence of the breastfeeding at 1 and 6 months after delivery (compared with the group of control, without intervention)

Study summary

Breastfeeding is the healthiest form of nutrition for the baby and is recommended to use exclusive breastfeeding (EB) until 6 months. The environmental footprint of artificial lactation (AL) has been studied, but that of EB is unknown.

Objectives:

The main objective of the first phase of the study is to identify the environmental impact in terms of the carbon footprint of breastfeeding and artificial breastfeeding, taking into account the accessories necessary for breastfeeding and of the diet and the factors associated with the diet of postpartum women in first month of life of the babies.

The main objective of the second phase is to evaluate the impact of a standardized intervention of educational programme on sustainable breastfeeding, diet and environment protection, providing inputs obtained from the first phase on the carbon footprint in the first month of life of the child and the prevalence of breastfeeding at the first month of the baby's life.

Eligibility

Sex
FEMALE
Min age
16 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * pregnant women over 16 years of age, between 24 and 32 weeks of gestation Exclusion Criteria: * women with a language barrier, under 16 years of age and those who do not want to participate or who do not give birth in the study associated centers

Primary outcome measure(s)

  • Rates (number of participants, %) that use breastfeeding (exclusive) up to 6 months after the delivery — months 30-36 of the project life
    The rate of breastfeeding (exclusive) will be observed up to 6 months after the participant's baby delivery and calucalted as a percentage or fraction compared to all participants: at month of the delivery (0 month) and 1, 3 and 6 months after the delivery (giving a birth)
  • Rates (number of participants, %) that use EB (excusive breastfeeding) in EG (experimental group) vs. CG (group of control) — months 30-36 of the project life
    Rates (number of participants, fractions or percentages) of breasfeeding will be calculated and compared in both groups: CG (control) vs. EG (experimental).

Trial sites (1)

FacilityCityRegionStatus
ASSIR Metropolitana Nord Sabadell Spain

More Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina trials in Spain

Experience With the Use of Continuous Glucose Monitoring (CGM) Devices in People With Type 2 Diabetes Mellitus Starting soon
Proactive Telemedicine to Improve Healthcare Access and Prevention in Rural Primary Care (PTM) Active, not recruiting
Clinical and Economic Evaluation of Point-of-care Ultrasound-guided Infiltration for Subacromial and Carpal Tunnel Syndromes in Primary Care: a Cluster-randomized Study Protocol. Active, not recruiting
throMboembolic Risk Associated To High atrIal Fibrillation riSk Starting soon
ACOMPANYEM: A COMmunity Program Accessing Lonely, Disabled Neighbors (Young, Elder, and Midlife) Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05729581 on ClinicalTrials.gov ↗ ← All trials in Spain